ASP 9276Alternative Names: ASP-9276
Latest Information Update: 16 Jul 2016
At a glance
- Originator Astellas Pharma
- Class Echinocandins
- Mechanism of Action Glucan synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Aspergillosis; Candidiasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Aspergillosis in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Candidiasis in USA
- 12 Sep 2012 Preclinical trials in Candidiasis in USA (unspecified route)